Alonso Galván

Co-Founder and Partner

Ehsan Jabbarzadeh Ph.D

Venture Partner

Dennis Sacha

Partner

Joel Whitley JD

Partner

54 past transactions

SixMap

Venture Round in 2025
SixMap is a technology company specializing in external attack surface management. Its platform detects and helps remediate network security policy issues by providing insights into potential cyberattack vectors.

T-robotics

Seed Round in 2025
T-Robotics specializes in developing AI-driven robot programming platforms. Their core technology employs end-to-end neural networks and constraint-based programming to train robots, enabling them to learn and execute complex tasks using natural language commands. This innovative approach enhances robots' performance, reduces programming complexity, and ensures compatibility with major commercial robot brands.

Swave Photonics

Series A in 2025
Swave Photonics designs and markets holographic chips based on proprietary diffractive photonics technology to power compact, lightweight, high-resolution displays that seamlessly blend digital content with the real world. As a fabless semiconductor company, it advances NanoPixel technology to enable immersive holographic displays for augmented reality and metaverse applications, targeting display manufacturers and content creators. The goal is to provide tools that visualize complex content, enable collaboration, and expand possibilities for immersive AR experiences.

Fluid Biomed

Series A in 2024
Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

Ayar Labs

Series D in 2024
Ayar Labs develops and manufactures high-density electronic-photonic chiplets and lasers, specializing in optical interconnect solutions. Its flagship product, TeraPHY, offers a monolithic in-package optical I/O solution for applications requiring high bandwidth, low latency, and power efficiency. The company's products serve various industries such as artificial intelligence, cloud computing, telecommunications, aerospace, and military.

Lightsynq

Series A in 2024
Lightsynq specializes in developing optical quantum interconnects, which are crucial components for large-scale quantum computers. Their platform employs integrated diamond photonic circuits, designed to be compatible with diverse quantum computing architectures. This technology facilitates fault-tolerant operations, high-fidelity quantum communication, and cross-platform connectivity, thereby addressing the system scaling challenges faced by the quantum computing industry.

Enfabrica

Series C in 2024
Enfabrica develops hardware, software, and system technologies to tackle interconnect bottlenecks in AI and accelerated computing workloads. It designs networking chips and converged memory fabric silicon and software to improve performance, scalability, and efficiency across hyper-scale cloud, edge, enterprise, and automotive infrastructure. The company focuses on technologies such as Compute Express Link to enable multi-GPU configurations and higher interconnect bandwidth, addressing bottlenecks in modern AI and data-intensive systems.

Xscape Photonics

Series A in 2024
Xscape Photonics specializes in developing photonic chips that enhance high-speed connections within data centers and high-performance computing systems. By harnessing photonics technology, the company offers scalable, energy-efficient solutions designed to facilitate advancements in AI, machine learning, and simulation hardware.

MIRIS

Seed Round in 2024
MIRIS provides spatial material and allows users to communicate with digital content.

CroíValve

Series B in 2024
CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

VenoStent

Series A in 2024
VenoStent develops bioabsorbable smart polymer wraps for vascular surgeries. Its flagship product, SelfWrap, is a perivascular wrap designed to reduce failures at the vein-artery junction in dialysis patients by promoting outward vein growth and providing custom-fit mechanical support. The company's technology acts as an external stent, reducing surgery time, infection risk, and wound reopening while improving vein usability and durability.

DeepCure

Series A in 2024
DeepCure Inc. is a biotechnology company based in Boston, Massachusetts, specializing in artificial intelligence-driven drug discovery. Founded in 2018, DeepCure develops innovative solutions for small-molecule drug development, utilizing advanced deep learning algorithms and a proprietary database of chemical compounds. The company offers services such as De-novo Lead Discovery, which employs AI algorithms to assess potential drug candidates from a virtual library, and Artificial Intelligence-driven Lead Optimization, aimed at enhancing drug development processes. Additionally, DeepCure's platform includes a molecular database designed to maximize the diversity and synthesizability of chemical compounds. By integrating AI predictive modeling and a feedback loop, DeepCure focuses on creating effective therapeutics for unmet medical needs, ultimately aiming to expedite the development of novel precision medicines.

Celestial AI

Series C in 2024
Celestial AI is a prominent artificial intelligence company that provides an advanced platform for users to efficiently create images, text, and presentations. Utilizing cutting-edge computer vision algorithms and natural language processing, the platform produces high-quality visual and textual content. Its intuitive design, combined with innovative features, facilitates easy content creation. Moreover, Celestial AI emphasizes intelligent data integration and prioritizes security, ensuring that users achieve impressive and reliable results.

RIOS

Series B in 2024
RIOS, founded in 2018, is a technology company helping global customers automate their factories, warehouses, and supply chain operations by deploying a new class of dexterous AI-powered robots. RIOS robots handle hard-to-automate tasks, typically requiring human-level dexterity, in unstructured environments. RIOS is headquartered in Palo Alto, CA and has a pilot facility in San Carlos, CA. More information is available at www.rios.ai.

NLX

Series A in 2024
NLX is a company that offers an end-to-end enterprise AI platform designed to enhance customer experiences for large brands. Its no-code, multimodal conversation platform allows organizations to create, monitor, and analyze automated conversations, leveraging machine learning and artificial intelligence. This technology enables personalized customer interactions through automated chat, voice, and multimodal conversations, facilitating effective self-service experiences. NLX's platform is highly scalable, integrated, and accessible anytime and anywhere, empowering brands to manage conversational deployments across their entire enterprise effectively.

Jana Care

Series B in 2023
Jana Care, Inc. is a company focused on developing mobile diagnostic solutions for the screening, management, and monitoring of chronic diseases. Its flagship products include The Aina Device, a self-monitoring tool for patients, and The Aina Station, a diagnostic solution for clinics and hospitals. These devices facilitate a range of tests, such as blood glucose, HbA1c, lipid profiles, creatinine, and hemoglobin. Additionally, Jana Care offers The Habits Program, a twelve-week digital coaching initiative aimed at managing diabetes and pre-diabetes. Founded in 2011 and headquartered in Boston, Massachusetts, with an additional office in Bengaluru, India, Jana Care was inspired by a challenge from a physician-entrepreneur to create innovative health solutions for remote communities in India, ultimately evolving into one of the largest chronic disease screening programs globally.

Fantix

Seed Round in 2023
Fantix is a no-code network of companies that collaborates to develop AI models using data abstraction and federated learning techniques. The platform enables predictive customer AI and federated insights by transforming data locally and only comparing abstractions to identify overlaps between datasets, producing aggregated, anonymous representations that remain encrypted. By avoiding pooling of user-level data, Fantix preserves privacy and business confidentiality while allowing participants to analyze cross-company patterns and derive meaningful insights without sharing raw data. The solution aims to level the playing field by enabling organizations to leverage shared learnings while maintaining data security and control over their information.

Enfabrica

Series B in 2023
Enfabrica develops hardware, software, and system technologies to tackle interconnect bottlenecks in AI and accelerated computing workloads. It designs networking chips and converged memory fabric silicon and software to improve performance, scalability, and efficiency across hyper-scale cloud, edge, enterprise, and automotive infrastructure. The company focuses on technologies such as Compute Express Link to enable multi-GPU configurations and higher interconnect bandwidth, addressing bottlenecks in modern AI and data-intensive systems.

Lucid Scientific

Series A in 2023
Lucid Scientific develops real-time cellular activity monitors for drug discovery and research. It serves academic institutions and pharmaceutical companies, offering innovative tools like RESIPHER for non-invasive, continuous measurement of oxygen consumption in cell cultures.

Swaybox Studios

Venture Round in 2023
Swaybox Studios is an animation studio based in Shreveport, Louisiana, specializing in the development of innovative animation technology and processes for film and television production. The company focuses on integrating practical puppetry into its projects, aiming to present this art form in new and engaging ways. By combining traditional techniques with modern storytelling, Swaybox Studios seeks to create visually stunning and emotionally resonant narratives that maintain the nostalgic charm of puppetry. Their approach emphasizes dynamic expressiveness and a human touch, offering audiences a unique viewing experience that stands out in contemporary media.

VenoStent

Series A in 2023
VenoStent develops bioabsorbable smart polymer wraps for vascular surgeries. Its flagship product, SelfWrap, is a perivascular wrap designed to reduce failures at the vein-artery junction in dialysis patients by promoting outward vein growth and providing custom-fit mechanical support. The company's technology acts as an external stent, reducing surgery time, infection risk, and wound reopening while improving vein usability and durability.

Celestial AI

Series B in 2023
Celestial AI develops a data center and artificial intelligence computing platform that uses photonics, mixed-signal ASICs, and advanced packaging to deliver sustainable improvements in AI acceleration hardware and software. Its Photonic Fabric technology enables optically scalable, disaggregated data center computing and memory, supporting deep learning and machine learning workloads. The company aims to provide an integrated platform that enhances AI performance while reducing energy use and total cost of ownership.

Ayar Labs

Series C in 2023
Ayar Labs develops and manufactures high-density electronic-photonic chiplets and lasers, specializing in optical interconnect solutions. Its flagship product, TeraPHY, offers a monolithic in-package optical I/O solution for applications requiring high bandwidth, low latency, and power efficiency. The company's products serve various industries such as artificial intelligence, cloud computing, telecommunications, aerospace, and military.

Graphiant

Series B in 2023
Graphiant is a Silicon Valley-based networking company focused on software-defined wide area networking. Founded in 2020, it develops SD-WAN technology and offers Graphiant Network Edge, a software-as-a-service platform that connects the enterprise WAN, hybrid cloud, network edge, customers, and partners, enabling rapid, enterprise-grade connectivity. Based in California, Graphiant aims to simplify and accelerate connectivity for large organizations by delivering agility and scalable network performance across on-premises, cloud, and edge environments.

Cognito Therapeutics

Series B in 2023
Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

NLX

Venture Round in 2022
NLX is a company that offers an end-to-end enterprise AI platform designed to enhance customer experiences for large brands. Its no-code, multimodal conversation platform allows organizations to create, monitor, and analyze automated conversations, leveraging machine learning and artificial intelligence. This technology enables personalized customer interactions through automated chat, voice, and multimodal conversations, facilitating effective self-service experiences. NLX's platform is highly scalable, integrated, and accessible anytime and anywhere, empowering brands to manage conversational deployments across their entire enterprise effectively.

Cornelis Networks

Series B in 2022
Cornelis Networks designs and markets high-performance networking products and purpose-built fabrics that accelerate scientific, commercial, and government workloads. Its solutions enable efficient scaling of computing, data analytics, and artificial intelligence tasks by aggregating processing power across many devices. The company serves government, academic institutions, and commercial enterprises through more than 500 global installations, helping customers achieve faster results and improved efficiency at scale.

UrbanFox

Seed Round in 2022
UrbanFox provides fraud protection for online merchants by applying proprietary generative AI, simulation and behavioral analysis to detect and prevent complex payment fraud. Its platform uses large behavioral models to track, identify and stop high-velocity payment and account fraud for online retailers, helping to reduce online credit and purchase scams.

Leuko

Series A in 2022
Leuko Labs, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in the development of healthcare equipment. The company's primary product, PointCheck, is a non-invasive device designed to monitor and count white blood cells. This innovative technology allows for more frequent testing of immunosuppressed patients, such as those undergoing chemotherapy, enhancing their quality of life and clinical outcomes. The device is particularly beneficial as it eliminates the need for invasive blood draws and laboratory infrastructure, making it more accessible and convenient for patients.

GeneCentric Therapeutics

Convertible Note in 2022
GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Ordaos Bio

Seed Round in 2022
Ordaos Bio is a biomedical research company based in Manhattan, New York, established in 2019. It focuses on revolutionizing drug discovery and development through the integration of artificial intelligence and biology. The company operates a human-enabled, machine-driven platform that facilitates the design of novel immunotherapies for oncology and chronic inflammatory diseases. By providing an AI-driven drug discovery pipeline, Ordaos Bio empowers researchers to develop treatments that are more effective and safer than conventional methods, thereby addressing significant challenges in medical research and enhancing therapeutic outcomes.

Elucid

Series B in 2022
Based in Boston's biotech hub, Elucid improves cardiovascular diagnostic imaging via machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software for evaluating plaque vulnerability from a single CT scan to inform risk assessment and treatment selection.

Ayar Labs

Series C in 2022
Ayar Labs develops and manufactures high-density electronic-photonic chiplets and lasers, specializing in optical interconnect solutions. Its flagship product, TeraPHY, offers a monolithic in-package optical I/O solution for applications requiring high bandwidth, low latency, and power efficiency. The company's products serve various industries such as artificial intelligence, cloud computing, telecommunications, aerospace, and military.

Lindy Biosciences

Series B in 2022
Founded in 2016, Lindy Biosciences specializes in developing protein-based therapeutic formulations using its proprietary Microglassification technology. This process converts proteins into stable, spherical microbeads, enabling high-concentration suspensions, encapsulation for controlled release, and dry powder pulmonary delivery.

CaliberMind

Series A in 2022
CaliberMind provides a B2B customer data platform for revenue marketers that integrates data, enables marketing attribution, engagement scoring, funnel insights, and churn analysis to optimize sales and marketing outcomes. Positioned as a buyer intelligence solution, the platform helps organizations leverage their sales, marketing, and customer data to improve productivity, engagement, and revenue through features such as account engagement, chain-based attribution, and marketing workflow automation, and by linking data across touchpoints to inform pipeline decisions and identify churn risk.

BeatBread

Seed Round in 2022
BeatBread is a music finance company that provides financial advances to independent and unsigned artists while preserving ownership of their music and control over their careers. Founded in 2020, it combines expertise in music, finance, and data analytics to offer advances that are repaid through a limited share of streaming and airplay revenue over a term chosen by the artist. The approach lets artists select collaborators and advance their careers on their own terms, without surrendering ownership or decision-making power.

Nanoligent

Seed Round in 2022
Nanoligent is a biotech company that originated as a spin-off from Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. The company focuses on the design and development of targeted therapeutic biologics, particularly in the realm of nanotechnology-based anti-cancer treatments. Utilizing advanced protein engineering and nanobiotechnology, Nanoligent creates self-assembling protein nanoparticles that selectively target and kill metastatic cancer cells. This innovative approach aims to enhance treatment effectiveness while minimizing adverse effects, ultimately striving to improve patient outcomes by developing medicines that directly address the cells affected by disease.

Tethr

Venture Round in 2021
Tethr is a company that specializes in providing an AI-driven communications intelligence platform designed to enhance enterprise decision-making by harnessing the Voice of the Customer. By analyzing customer interactions from various communication channels, including phone calls and chats, Tethr extracts valuable insights that help organizations understand customer sentiment and behavior. With a foundation built on over a decade of best-practice customer experience research, Tethr equips businesses to measure key performance indicators that affect sales, customer loyalty, operating costs, compliance, and risk management. The platform enables organizations to share these insights across their teams, fostering a culture of informed decision-making that directly impacts overall business performance.

GeneCentric Therapeutics

Series B in 2021
GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

First Ascent Biomedical

Pre Seed Round in 2021
First Ascent Biomedical is a biotechnology company that employs artificial intelligence to design personalized cancer treatment plans. Its platform uses AI and therapy-resistant cell technologies to offer affordable, effective treatment options, reducing failed regimens.

New View Surgical

Series B in 2021
New View Surgical, Inc. is an innovative medical device company based in Boston, Massachusetts, focused on the development and commercialization of the VisionPort technology. Founded in 2009, the company has created a novel surgical imaging and access system designed specifically for minimally invasive surgery. The VisionPort system consolidates four essential surgical devices—laparoscope, camera, light source, and access port—into a single, user-friendly, disposable device. This integration provides surgeons with enhanced control over both visualization and instrumentation, aiming to address various unmet needs in the market. By simplifying the surgical process, New View Surgical seeks to deliver significant clinical and economic advantages to operating rooms worldwide.

UpGuard

Series B in 2021
UpGuard Inc. is a cybersecurity company that provides a comprehensive platform aimed at assessing and managing cyber risks. Founded in 2012 and headquartered in Mountain View, California, UpGuard offers tools such as the CyberSecurity Threat Assessment Report (CSTAR), which evaluates an organization's IT infrastructure and assigns a risk score that reflects potential vulnerabilities. Its solutions include integrity monitoring, configuration differencing, and advanced vulnerability analytics, which help clients identify security gaps and streamline compliance efforts. Additionally, UpGuard's platform automates the documentation of configuration states for servers and network devices, facilitating better risk assessment and management. The company's technology is utilized by numerous organizations, including major corporations, to enhance their security posture, improve DevOps initiatives, and support cybersecurity insurance procurement. UpGuard was previously known as ScriptRock Inc. before rebranding in January 2016.

Elucid

Series A in 2021
Based in Boston's biotech hub, Elucid improves cardiovascular diagnostic imaging via machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software for evaluating plaque vulnerability from a single CT scan to inform risk assessment and treatment selection.

VenoStent

Seed Round in 2021
VenoStent develops bioabsorbable smart polymer wraps for vascular surgeries. Its flagship product, SelfWrap, is a perivascular wrap designed to reduce failures at the vein-artery junction in dialysis patients by promoting outward vein growth and providing custom-fit mechanical support. The company's technology acts as an external stent, reducing surgery time, infection risk, and wound reopening while improving vein usability and durability.

OpenDrives

Series B in 2021
OpenDrives LLC is a company that specializes in developing high-performance network-attached storage (NAS) solutions tailored for industries reliant on high-resolution video and imaging, such as broadcast, video editing, and visual effects. Founded in 2015 and based in Culver City, California, OpenDrives offers a range of products including Avalanche, an all-flash storage system designed for demanding workflows; Spectre, a hybrid storage system that adapts to changing production needs; and Ridgeview, a high-density solution for nearline and active archiving. Additionally, the company provides OPUS, an enterprise-grade management platform aimed at enhancing operational efficiency in the media and entertainment sectors. OpenDrives focuses on enabling clients to manage large volumes of data with high concurrency, ensuring optimal performance and seamless workflows.

Coagulo Medical Technologies

Venture Round in 2020
Coagulo Medical Technologies develops portable precision-medicine platforms for managing coagulation disorders. Its systems detect, identify, and quantify the effects of anticoagulants in whole blood, providing actionable results to healthcare providers.

CoreCare

Seed Round in 2020
CoreCare is an AI-powered platform for post-acute and long-term care providers that integrates and standardizes data from disparate systems to streamline billing and reimbursement processes. The platform replaces spreadsheets and fragmented portals with automated workflows, enabling admissions optimization, improved reimbursement rates, and stronger cash flow while reducing administrative burdens. Its Collaborative Revenue Management unites data and teams on a single platform, providing visibility into performance and enabling staff to reconcile and reconsider reimbursements efficiently. CoreCare is based in Fort Worth, Texas.

Obsidio

Venture Round in 2020
Obsidio, Inc. is a medical device company based in Solana Beach, California, founded in 2018. The company specializes in developing shear-thinning hydrogel biomaterial technology, which is utilized to create therapeutic devices and universal gel embolization materials. This innovative technology allows for minimally invasive embolization procedures to effectively stop unwanted blood flow in vessels throughout the body. Obsidio's products are designed to address a variety of medical issues, including hemorrhage, aneurysms, and cancers, by providing targeted control of bleeding and occlusion of blood vessels. The company's biomaterial platform is applicable in interventional radiology and oncology, enabling precise and durable treatment solutions.

Zopa

Series H in 2019
Zopa is a UK-based online marketplace lending platform that connects borrowers with lenders directly, bypassing traditional banks. The platform provides unsecured consumer loans including car finance, debt consolidation, home improvement, and wedding loans, and supports peer-to-peer investments. Funds come from individuals and institutions, and money lent to a borrower is typically spread across many lenders. Borrowers repay monthly by direct debit under signed contracts, while lenders can fund small portions of multiple loans. The service includes an app to manage loans, credit, and savings, and to monitor credit scores. Zopa generates revenue by charging borrowers a fixed fee and lenders a 1% annual fee. The company is based in London and was founded in 2004.

Tethr

Venture Round in 2019
Tethr is a company that specializes in providing an AI-driven communications intelligence platform designed to enhance enterprise decision-making by harnessing the Voice of the Customer. By analyzing customer interactions from various communication channels, including phone calls and chats, Tethr extracts valuable insights that help organizations understand customer sentiment and behavior. With a foundation built on over a decade of best-practice customer experience research, Tethr equips businesses to measure key performance indicators that affect sales, customer loyalty, operating costs, compliance, and risk management. The platform enables organizations to share these insights across their teams, fostering a culture of informed decision-making that directly impacts overall business performance.

Lindy Biosciences

Series A in 2019
Founded in 2016, Lindy Biosciences specializes in developing protein-based therapeutic formulations using its proprietary Microglassification technology. This process converts proteins into stable, spherical microbeads, enabling high-concentration suspensions, encapsulation for controlled release, and dry powder pulmonary delivery.

Grips Intelligence

Seed Round in 2018
Grips Intelligence is an e-commerce market research platform that specializes in transforming data from websites into actionable insights for manufacturers, retailers, and investors. By leveraging advanced machine learning technology, Grips Intelligence enables businesses to optimize their online sales performance through functions such as website categorization and cross-domain product mapping. The platform provides valuable transactional intelligence data, helping thousands of companies worldwide identify growth opportunities and enhance their performance in the competitive e-commerce landscape. With its focus on delivering data-driven insights, Grips Intelligence supports its clients in making informed decisions that unlock their full potential in the market.

PATH EX

PATH EX develops a proprietary technology for extracorporeal blood cleansing, focusing on treating sepsis by selectively removing intact bacteria and toxins from human blood. This innovative approach aims to reduce diagnostic times, treatment costs, readmission rates, and sepsis-related deaths.

Graphiant

Graphiant is a Silicon Valley-based networking company focused on software-defined wide area networking. Founded in 2020, it develops SD-WAN technology and offers Graphiant Network Edge, a software-as-a-service platform that connects the enterprise WAN, hybrid cloud, network edge, customers, and partners, enabling rapid, enterprise-grade connectivity. Based in California, Graphiant aims to simplify and accelerate connectivity for large organizations by delivering agility and scalable network performance across on-premises, cloud, and edge environments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.